Impact of relatively new chemotherapeutic agents on the outcome of Egyptian patients with advanced malignant pleural mesothelioma

[1] Gaafar R, Aly Ely Eldin N; Epidemic of mesothelioma in Egypt, Lung Cancer, 2005, 49S1, S17-S20.10.1016/j.lungcan.2005.03.025Search in Google Scholar

[2] Abou El-Kasem F, Gaafar R, Abdel-Rahman A, Abdel-Baki H, Hassan N. Malignant pleural mesothelioma: analysis of 100 consecutive patients. Lung Cancer 2004, 45(3):s67.Search in Google Scholar

[3] Porret E, Madelaine J, Galateau-Salle F, et al. Epidemiology, molecular biology, diagnostic and therapeutic strategy of malignant pleural mesothelioma in 2007-an update. Rev Mal Respir 2007; 24:6S157-64. [PubMed]10.1016/S0761-8425(07)78149-4Search in Google Scholar

[4] Van Schil PE, Baas P, Gaafar R, et al. Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial. Eur Respir J 2010;36:1362-9.10.1183/09031936.00039510Search in Google Scholar

[5] Hillerdal G, Sorensen JB, Sundstrom S, et al. Treatment of malignant pleural mesothelioma with carboplatin, liposomized doxorubicin, and gemcitabine: a phase II study. J Thorac Oncol 2008; 3:1325-[6] van Meerbeeck JP, Baas P, Debruyne C, et al: EORTC Lung Cancer Group. A phase II EORTC study of temozolomide in patients with malignant pleural mesothelioma. Eur J Cancer 2002, 38, 779-783.Search in Google Scholar

[7] Habib EE, Fahmy ES. Chemotherapy management of malignant pleural mesothelioma: a phase II study comparing two popular chemotherapy regimens. Clin Transl Oncol. 2013 [Epub ahead of print] [PubMed]10.1007/s12094-013-1015-3Search in Google Scholar

[8] van Meerbeeck J, Debruyne C, van Zandwijk N, et al: Paclitaxel for malignant pleural mesothelioma: A phase II studies of the EORTC Lung Cancer Cooperative Group. Br J Cancer, 1996, 74, 961-963.10.1038/bjc.1996.465Search in Google Scholar

[9] Scherpereel A, Astoul P, Baas P, et al. Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. Eur Respir J 2010; 35: 479-95.10.1183/09031936.00063109Search in Google Scholar

[10] Sahmoud T, Postmus PE, van Pottelsberghe C, et al: G. Etoposide in malignant pleural mesothelioma: Two phase II trials of the EORTC Lung Cancer Cooperative Group. Eur J Cancer,1997, 33, 2211-2115.10.1016/S0959-8049(97)00183-4Search in Google Scholar

[11] Ellis P, Davies AM, Evans WK, etal: The use of chemotherapy in patients with advanced malignant pleural mesothelioma: a systemic review and practice guide lines. J Thoracic Oncol, 2006, 1(6), 591-601.10.1016/S1556-0864(15)30366-XSearch in Google Scholar

[12] Shin DM, Scagliotti GV, Kindler HL, et al: A phase II trial of pemetrexed in malignant pleural mesothelioma (MPM) patients: Clinical outcome, role of vitamin supplementation, respiratory symptoms and lung function. Proc Am Soc Clin Oncol, 2002, 21, 294 (abstr 1175).Search in Google Scholar

[13] Vogelzang N, Rusthoven J., Symanowski J., etal phase III Study of Pemetrexed in Combination With CisplatinVersus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma, J Clin Oncol 2003, 21, 2636-2644.10.1200/JCO.2003.11.136Search in Google Scholar

[14] Baas P, Ardizzoni A, Grossi F, et al: EORTC Lung Cancer Group: The activity of raltitrexed (Tomudex) in malignant pleural mesothelioma: An EORTC phase II study (08992). Eur J Cancer 2003, 39, 353-357.10.1016/S0959-8049(02)00668-8Search in Google Scholar

[15] Fizazi K, Doubre H, Le Chevalier T, et al: Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma: Results of a phase II study. J Clin Oncol 2003, 21, 349- 354.10.1200/JCO.2003.05.12312525529Search in Google Scholar

[16] van Meerbeeck JP, Gaafar R, Manegold C, et al. Randomized phase IIIstudy of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 2005;23: 6881-9.10.1200/JCO.20005.14.58916192580Search in Google Scholar

[17] Ceresoli GL, Zucali PA, Favaretto AG, et al. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. J Clin Oncol 2006; 24:1443.10.1200/JCO.2005.04.319016549838Search in Google Scholar

[18] Castagneto B, Botta M, Aitini E, et al. Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM). Ann Oncol 2008; 19:370.10.1093/annonc/mdm50118156144Search in Google Scholar

[19] Santoro A, O’Brien ME, Stahel RA, et al. Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access Program. J Thorac Oncol 2008; 3:756.10.1097/JTO.0b013e31817c73d618594322Search in Google Scholar

[20] Laurie SA, Gupta A, Chu Q, et al. Brief report: a phase II study of sunitinib in malignant pleural mesothelioma. The NCIC Clinical Trials Group. J Thorac Oncol 2011; 6:1950-4.10.1097/JTO.0b013e3182333df522005473Search in Google Scholar

[21] Kindler HL, Karrison TG, Gandara DR, et al. Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma. J Clin Oncol 2012; 30:2509-15.10.1200/JCO.2011.41.5869339778522665541Search in Google Scholar

[22] Zucali PA, Ceresoli GL, De Vincenzo F, et al. Advances in the biology of malignant pleural mesothelioma. Cancer Treat Rev 201; 37:543-58. [PubMed]10.1016/j.ctrv.2011.01.00121288646Search in Google Scholar